Abstract
The dendritic cell (DC) is a potentially promising tool for cancer immunotherapy. To date, however, DC-based immunotherapy has not yielded data with which firm conclusions can be drawn. In the present study, we tested the dose-dependant enhancement of the anti-tumor effect induced by DCs. When large numbers of DCs were used, tumor growth was suppressed up to 41% when compared to control mice. Survival of the animals was prolonged to 54 days compared to the 33-day survival the control mice. The delayed-type hypersensitivity (DTH) response induced was 26-fold higher than in the controls. Larger numbers of DCs also led to higher expansion of IFN-γ-secreting-CD8+ T cells. Furthermore, the secretion of IL-12p70 and IFN-γ by spleen cells were enhanced in proportion to the dosage. However, the level of IL-4 secreted from spleen cells was negligible compared to the level of IFN-γ that was released. These results indicate that DCs induce Th1-dominant immune response and that more DCs could lead to better immunological results, a finding which was consistent with our therapeutic results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chen Z, Moyana T, Saxena A et al (2001) Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 93:539–548
Cranmer LD, Trevor KT, Hersh EM (2004) Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 53:275–306
Eggert AA, Schreurs MW, Boerman OC et al (1999) Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59:3340–3345
Lambert LA, Gibson GR, Maloney M et al (2001) Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 61:641–646
Morse MA, Deng Y, Coleman D et al (1999) A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcino-embryonic antigen. Clin Cancer Res 5:1331–1338
Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332
Okada N, Tsujino M, Hagiwara Y et al (2001) Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br J Cancer 84:1564–1570
Ragde H, Cavanagh WA, Tjoa BA (2004) Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 172:2532–2538
Timmerman JM, Czerwinski DK, Davis TA et al (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517–1526
Wright-Browne V, McClain KL, Talpaz M et al (1997) Physiology and pathophysiology of dendritic cells. Human Pathol 28:563–579
Acknowledgements
This work was supported by a Grant (04092-495) from the Korean Food and Drug Administration.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, TH., Cho, YH. & Lee, MG. Larger numbers of immature dendritic cells augment an anti-tumor effect against established murine melanoma cells. Biotechnol Lett 29, 351–357 (2007). https://doi.org/10.1007/s10529-006-9260-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10529-006-9260-y